InsidersTradesSigma
Track the Veeva Systems INC stock price and the full insider trade history of the company, a listed issuer based in United States. Shares are quoted on the US market, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Veeva Systems INC has logged 571 insider filings. Market capitalisation: €39.6bn. The latest transaction was filed on 17 August 2026 (Cession). Among the most active insiders: Schwenger Thomas D.. The full history is accessible without an account.
571
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
€30m
127 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Veeva Systems INC Buy (bullish), based on 28 analysts. Average price target: US$244.14.
45Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 8,609 of 28,958 companies
61.6
score / 100
Value37
Quality86
FCF yld3.6%
Earn yld2.3%
EV/EBITDA41.8x
ROE14%
Gross mgn76%
Net mgn28%
Debt/EBITDA0.1x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 17 August 2026
Declarations571 total
1,000 shares@ US$241.91Class A Common StockSEC:0001628280-26-057403:0
35,000 shares@ US$154.00Class A Common StockSEC:0001628280-26-057403:1
33,181 shares@ US$250.4403Class A Common StockSEC:0001628280-26-057403:2
1,819 shares@ US$251.028Class A Common StockSEC:0001628280-26-057403:3
5,000 shares@ US$200.000.0031% mcap31.7% of flowClass A Common StockSEC:0001628280-26-048823:0
832 shares@ US$184.220.0005% mcap6.2% of flowClass A Common StockSEC:0001628280-26-047262:1
60 shares@ US$184.220.0000% mcap100.0% of flowClass A Common StockSEC:0001628280-26-047266:1
1,117 shares@ US$184.220.0007% mcap11.7% of flowClass A Common StockSEC:0001628280-26-047268:1
693 shares@ US$184.220.0004% mcap100.0% of flowClass A Common StockSEC:0001628280-26-047273:1
167 shares0Class A Common StockSEC:0001628280-26-047266:0
2,907 shares0Class A Common StockSEC:0001628280-26-047268:0
1,635 shares0Class A Common StockSEC:0001628280-26-047273:0
1,635 shares0Class A Common StockSEC:0001628280-26-047262:0
2,180 shares0Class A Common StockSEC:0001628280-26-047278:0
262 shares0Class A Common StockSEC:0001628280-26-040405:0
271 shares0Class A Common StockSEC:0001628280-26-040400:0
750 shares@ US$155.640.0004% mcap25.1% of flowClass A Common StockSEC:0001628280-26-029800:0
750 shares@ US$153.500.0004% mcap24.9% of flowClass A Common StockSEC:0001628280-26-025087:0
7,500 shares0Class A Common StockSEC:0001628280-26-023622:0
1,226 shares0Class A Common StockSEC:0001628280-26-023622:2
2,500 shares0Class A Common StockSEC:0001628280-26-023632:0
103 shares0Class A Common StockSEC:0001628280-26-023632:2
2,043 shares0Class A Common StockSEC:0001628280-26-023636:0
7,500 shares0Class A Common StockSEC:0001628280-26-023626:0
1,498 shares0Class A Common StockSEC:0001628280-26-023626:2
25 of 571 declarations
About Veeva Systems INC
Veeva Systems Inc. is a U.S.-based enterprise software company focused on cloud software, data, artificial intelligence, and consulting for the global life sciences industry. The company is listed in the United States on the NYSE under the ticker VEEV. It was founded in 2007, and its headquarters are in Pleasanton, California, United States. Veeva’s business model is built around a vertical industry platform designed for the operational, regulatory, and commercial needs of pharmaceuticals, biotechnology companies, and other highly regulated life sciences organizations. Its core product stack spans Vault Platform, Vault CRM, Veeva Quality Cloud, Veeva Clinical, Veeva Regulatory, Veeva Safety, Veeva Medical, Veeva Commercial Cloud, and Veeva Data Cloud. More recently, the company has been pushing Veeva AI, a set of domain-specific AI capabilities and agents intended to work deeply inside Veeva applications. This is strategically important because Veeva is not selling generic software; it is offering workflow-heavy, compliance-aware applications tailored to the life sciences value chain. From a competitive standpoint, Veeva holds a leading position in vertical cloud software for life sciences. Its moat is driven by industry specialization, long customer relationships, recurring subscription revenues, and the breadth of its platform, which extends from R&D and clinical operations to quality, regulatory, medical affairs, and commercial execution. In recent corporate communications, Veeva has highlighted the expansion of Vault CRM, growing adoption of Veeva Basics by emerging biotechs, and early momentum around AI-enabled products. That combination reinforces the company’s reputation as a mission-critical vendor rather than a discretionary IT provider. Geographically, Veeva serves customers globally, with a commercial footprint and support capabilities across multiple regions, while maintaining its corporate base in California. Recent notable developments include the rollout of Veeva AI Agents across applications, new biotech-focused product introductions, collaboration announcements related to clinical-trial innovation, and strong quarterly results in 2025 and early 2026, supported by solid subscription revenue growth. For investors, Veeva stands out as a high-quality growth name in the Health & Pharma sector, with exposure to a structurally resilient end market and a differentiated software franchise built on deep domain expertise.
